Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Dorzolamide Hcl 2% Drops 10 Ml By Teva Pharma.

Image 0 of Dorzolamide Hcl 2% Drops 10 Ml By Teva Pharma.Image 1 of Dorzolamide Hcl 2% Drops 10 Ml By Teva Pharma.

Dorzolamide Hcl 2% Drops 10 Ml By Teva Pharma.

CALL US FOR THE PRICE

Dorzolamide Hcl 2% Drops 10 Ml By Teva Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4278800/RXB10003564/RXA600674
Size : 10 ML
Selling UoM : EA
NDC: 00093-7618-43
UPC Barcode : 300937618430
Supplier: 0050001781 TEVA PHARMACEUTICALS USA
Supplier Material : 761843
Generic Code : 023513 DORZOLAMIDE HCL OPHTHALMIC DROPS 2 %
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type

Have a question?

  CALL US FOR THE PRICE

Product Description.:

Drops , clear , clear

TRUSOPT (dorzolamide hydrochloride ophthalmic solution) is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.

Dorzolamide hydrochloride is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6?methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride.

Dorzolamide hydrochloride has a molecular weight of 360.9 and a melting point of about 264?C. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.

TRUSOPT Sterile Ophthalmic Solution is supplied as a sterile, isotonic, buffered, slightly viscous, aqueous solution of dorzolamide hydrochloride. The pH of the solution is approximately 5.6, and the osmolarity is 260-330 mOsM. Each mL of TRUSOPT 2% contains 20 mg dorzolamide (22.3 mg of dorzolamide hydrochloride). Inactive ingredients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide (to adjust pH) and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.

INDICATIONS

TRUSOPT Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

DOSAGE AND ADMINISTRATION

The dose is one drop of TRUSOPT Ophthalmic Solution in the affected eye(s) three times daily. TRUSOPT may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.

SIDE EFFECTS

Controlled clinical trials: The most frequent adverse events associated with TRUSOPT were ocular burning, stinging, or discomfort immediately following ocular administration (approximately one-third of patients). Approximately one-quarter of patients noted a bitter taste following administration. Superficial punctate keratitis occurred in 10-15% of patients and signs and symptoms of ocular allergic reaction in approximately 10%. Events occurring in approximately 1-5% of patients were conjunctivitis and lid reactions (see PRECAUTIONS, General), blurred vision, eye redness, tearing, dryness, and photophobia. Other ocular events and systemic events were reported infrequently, including headache, nausea, asthenia/fatigue and, rarely, skin rashes, urolithiasis, and iridocyclitis.

In a 3-month, double-masked, active-treatment-controlled, multicenter study in pediatric patients, the adverse experience profile of TRUSOPT was comparable to that seen in adult patients.

Clinical practice: The following adverse events have occurred either at low incidence ( < 1%) during clinical trials or have been reported during the use of TRUSOPT in clinical practice where these events were reported voluntarily from a population of unknown size and frequency of occurrence cannot be determined precisely. They have been chosen for inclusion based on factors such as seriousness, frequency of reporting, possible causal connection to TRUSOPT, or a combination of these factors: signs and symptoms of systemic allergic reactions including angioedema, bronchospasm, pruritus, and urticaria dizziness, paresthesia ocular pain, transient myopia, choroidal detachment following filtration surgery, eyelid crusting dyspnea contact dermatitis, epistaxis, dry mouth and throat irritation.